TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01024452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DAWN AC
Description: computerized dosing management system for anticoagulation clinics

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton Nomogram
Description: simple nomogram for warfarin maintenance dosing
Study: NCT04403477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Apheretic convalescent plasma from a COVID-19 survivor
Study: NCT02378779

Intervention type: OTHER
Group type: OTHER
Intervention: Questionary SF12 and PEDT (Premature Ejaculation Diagnostic Tool)
Description: The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).

Intervention type: OTHER
Group type: OTHER
Intervention: Total attention
Description: Total attention of the GP to approach the subject of premature ejaculation during all the consultation

Intervention type: OTHER
Group type: OTHER
Intervention: Humour
Description: Use the humour to approach the subject of premature ejaculation

Intervention type: OTHER
Group type: OTHER
Intervention: Take the drama out
Description: Take the drama out to approach the subject of premature ejaculation

Intervention type: OTHER
Group type: OTHER
Intervention: Question about premature ejaculation
Description: Question about premature ejaculation during the GP consultation

Intervention type: OTHER
Group type: OTHER
Intervention: Symptoms of premature ejaculation
Description: GP's observation about signs of premature ejaculation

Intervention type: OTHER
Group type: OTHER
Intervention: Help to verbalize
Description: Help for the patient to speak about premature ejaculation
Study: NCT04444804

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: Dosage at the discretion of the treating physician

Intervention type: DRUG
Intervention: LMWH and Phenprocoumon
Description: Dosage at the discretion of the treating physician
Study: NCT01913314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^14C]-LY2835219
Description: Administered as oral solution
Study: NCT03829436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 TPST-1120
Description: Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 TPST-1120 + nivolumab
Description: Subjects will receive escalating doses of TPST-1120 administered orally twice daily
Study: NCT05482724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Super Skills for Life
Description: Structured and manualized intervention with a manual for the therapist and a workbook for the children.~Spanish version of Super Skills for Life group program: Orgilés, M., Espada, J.P., Ollendick, T.H. \& Essau, C. (2022). Programa Super Skills. Manual del aplicador. Elche, ES: Universidad Miguel Hernández.~The intervention was administered by a trained clinical psychologist in SSL. Sessions were held after school hours once a week for eight weeks, with each session lasting approximately one hour. The contents of the program were covered through playful activities in groups of 4 to 6 children
Study: NCT03258437

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DA-9401

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks.
Study: NCT02412475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
Study: NCT03829436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 3 TPST-1120
Description: Selected dose of TPST-1120 administered orally twice daily until disease progression
Study: NCT02412475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
Study: NCT03829436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 4 TPST-1120 + nivolumab
Description: Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
Study: NCT02226536

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: fractioned diet without glucose
Description: Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: fractioned diet without glucose
Description: Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
Study: NCT04091178

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VITAMIN D
Description: ORAL SOLUTION (2 ml) at 100.000 UI
Study: NCT02867072

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open appendectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic appendectomy
Study: NCT03752034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Fiber Fragments (MFFs)
Description: During the rotator cuff repair procedure, a biopsy of muscle will be taken from the pectoralis major and processed under sterile conditions in the operating room to obtain MFFs. The final product, composed of autologous MFFs in suspension, will be delivered via targeted injection into the muscle belly of the supraspinatus through the Naviaser Portal with visual guidance after rotator cuff repair is complete.
Study: NCT02824458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Patients will be treated with Gefitinib, 250 mg p.o., daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib
Description: Patients will be treated with Gefitinib, 250 mg p.o., daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04337931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotigalimab
Description: Sotigalimab is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotigalimab
Description: Sotigalimab is a CD40 agonistic monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sotigalimab
Description: Sotigalimab is a CD40 agonistic monoclonal antibody
Study: NCT04321603

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Walking
Description: Moderately paced walking of approximately 100 steps/minute for 30 minutes three times weekly for six weeks.
Study: NCT01435252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
Study: NCT01821989

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: dose of 100 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: dose of 150 mg/kg/ twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: in form of distilled water
Study: NCT04570358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: During the static stretching training for the calf muscles, the ankle joint is moved into maximal dorsiflexion until the point of discomfort is reached. The ankle joint is then held in this maximal position for 30 s followed by a rest period of 30 s. Afterwards, the procedure is repeated with the knee in flexed position to stretch the soleus muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation stretching
Description: During the proprioceptive neuromuscular facilitation stretching, the ankle joint is moved into maximal dorsiflexion. While the foot is kept in this position, the child will perform a (sub-) maximal isometric contraction of the plantar flexors against the resistance of their parents. Afterwards, the ankle joint will be moved further into greater dorsiflexion and is held there for the remaining seconds followed by 30 s of rest. Subsequently, the stretch will be applied with the knee flexed.
Study: NCT00934817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl-M 2/500 mg
Description: single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amaryl-M 2/500 mg
Description: single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl-M 1/500 mg
Description: single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amaryl-M 1/500 mg
Description: single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
Study: NCT03102034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D46/NS2/N/ΔM2-2-HindIII
Description: 10\^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic diluent; administered as nose drops
Study: NCT01811394

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: protons
Description: Treatment is performed using 16 x 4 GyE protons

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ions
Description: Treatment is performed using 16 x 4 GyE carbon ions
Study: NCT03908775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC videolaryngoscope
Description: An intubating device that is used for nasotracheal intubation in children undergoing dental interventions. Nasotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscope
Description: An intubating device that is used for nasotracheal intubation. Nasotracheal intubation was applied by anesthesiologist with direct laryngoscope.
Study: NCT00111683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0457
Study: NCT01662154

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurometer assessment
Description: Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve stimulator assessment
Description: Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
Study: NCT02282657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECCO2R will be initiated during the 2-hour run-in time
Description: A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).~Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.~Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.~Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (NMBA)
Description: Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation
Description: Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Level of carbon dioxide released at the end of expiration
Description: EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Rate
Description: RR will be kept what it was at baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweep gas flow
Description: Sweep gas flow will be adapted to maintain the same EtCO2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation will be adapted
Description: If PaCO2\> 75 mmHg and/or pH \< 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory rate will be adapted
Description: If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
Study: NCT02957799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accountable Condition
Description: Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive ongoing monitoring and supervision. CHW will monitor mother's health and linkage to care; CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. CHW will also have a mobile phone to record information at each visit. CHW will log their home visits each day, rate the content and skills addressed on the mobile phone, weigh children, and report outcome achievements (e.g., receiving the child grant, immunizations, breastfeeding, and retention/ adherence to HIV care). The CHW in this arm will receive data-informed supervision. CHW will be monitored weekly with review of contact logs, recorded outcomes, and random site visits by supervising in-service training on a monthly basis. The Accountable Condition will last for two years (until the child is 24 months old).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Condition
Description: Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive supervision and monitoring consistent with local government practices. CHW will monitor mother's health and linkage to care. CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. The Control Condition will last for two years (until the child is 24 months old).
Study: NCT03642106

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Unidos Se Puede
Description: The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unidos Se Puede
Description: The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
Study: NCT04177147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support via alert tool
Description: The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
Study: NCT04365114

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Screening Mammography with single reader
Description: One clinician examined each woman's mammograms for signs of cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast screening mammography with two readers
Description: Two clinicians seperately examined each woman's mammograms for signs of cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: Test threshold
Description: Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled

Intervention type: DIAGNOSTIC_TEST
Intervention: Test threshold
Description: Threshold used by readers examining the breast screening mammograms, defined using their previous proportion of cases recalled
Study: NCT04686799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hyclate 20 MG
Description: Subjects will receive doxycycline 20 mg BID
Study: NCT04532801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10
Description: kisspeptin-10 IV infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mixed meal tolerance test
Description: mixed meal tolerance test

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mixed meal tolerance test
Description: mixed meal tolerance test
Study: NCT01654133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft
Description: Repair of thoracoabdominal aortic aneurysms

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular repair of ascending/arch aortic aneurysm using branched stent graft
Description: Repair of ascending/arch aortic aneurysms
Study: NCT01879748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will be enrolled into 1 of 4 cohorts:~* cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~* cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~* rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~* rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~* placebo (8 Japanese and 8 Caucasian subjects)
Study: NCT02264470

Intervention type: OTHER
Intervention: Not relevant
Description: Not relevant
Study: NCT04675619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral pirfenidone
Description: Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Treatment
Study: NCT04128020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab
Study: NCT02412475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: 5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Patient Age (years) IT Cytarabine Dose \> 1 30 mg~* 2 and \< 3 50 mg~* 3 and ≤ 18 70 mg \> 18 100 mg~given IT on day 0 or -1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 150 mg/m2/dose twice daily by mouth on days 11-28
Study: NCT03792698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aidcube digital app-based platform
Description: Use of customizable, patient-specific mHealth home rehabilitation plan
Study: NCT04128020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine
Study: NCT01676415

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days~Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical mometasone
Description: Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study.